Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Magnesium sulfate injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia. It reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction.
Lead Product(s): Magnesium Sulfate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Magnesium Sulfate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Athenex
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.
Lead Product(s): Pyridostigmine
Therapeutic Area: Immunology Product Name: Pyridostigmine Bromide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Milla Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Maxigesic IV (a unique combination of 1000 mg paracetamol and 300 mg ibuprofen solution for infusion) is a novel, patented, non-opioid pain treatment, and is being commercialised by Hyloris’ partner AFT Pharmaceuticals.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Product Name: Maxigesic IV
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hyloris Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 24, 2021